Novartis Suffers Setback As Indian Patent Appeals Board Strikes Down Glivec Patent
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Hopes for Novartis to obtain a product patent for its chronic myeloid leukemia drug Gleevec (imatinib) were dashed after India's Intellectual Property Appellate Board ruled that Novartis' patent application covering the medicine's beta-crystalline version is not patentable because it failed to satisfy the requirements under Section 3(d) of the India Patents Act
You may also be interested in...
Novartis Says Adverse Gleevec Ruling Would Impact Outlook For India
As India’s Supreme Court prepares to deliver a landmark verdict next week on the patentability of Gleevec, Novartis prepares for stormy weather.
President Obama May Take Up IP Protection Issue During India Visit
MUMBAI - One of the top priorities for U.S. President Barack Obama during his four day visit to India may be to seek strengthened IP rights protection from the Indian government - a thorny issue that has kept some multinational companies away from committing R&D investments in the country despite availability of a large pool of scientists and significant cost advantages
President Obama May Take Up IP Protection Issue During India Visit
MUMBAI - One of the top priorities for U.S. President Barack Obama during his four day visit to India may be to seek strengthened IP rights protection from the Indian government - a thorny issue that has kept some multinational companies away from committing R&D investments in the country despite availability of a large pool of scientists and significant cost advantages